SV2008002527A - Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato ref. p-sv-80.273/ug - Google Patents

Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato ref. p-sv-80.273/ug

Info

Publication number
SV2008002527A
SV2008002527A SV2006002527A SV2006002527A SV2008002527A SV 2008002527 A SV2008002527 A SV 2008002527A SV 2006002527 A SV2006002527 A SV 2006002527A SV 2006002527 A SV2006002527 A SV 2006002527A SV 2008002527 A SV2008002527 A SV 2008002527A
Authority
SV
El Salvador
Prior art keywords
organization
methyl
folate
tetrahydropholate
pharmaceutical composition
Prior art date
Application number
SV2006002527A
Other languages
English (en)
Spanish (es)
Inventor
Kai Strothmann
Smith Gavin Welch
Hatmut Blode
Kristina Muller
Rudolf Moser
Original Assignee
Schering Ag
Merck Eprova Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37396913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2008002527(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102005023301A external-priority patent/DE102005023301B4/de
Priority claimed from DE102006016285A external-priority patent/DE102006016285A1/de
Application filed by Schering Ag, Merck Eprova Ag filed Critical Schering Ag
Publication of SV2008002527A publication Critical patent/SV2008002527A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
SV2006002527A 2005-05-13 2006-05-12 Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato ref. p-sv-80.273/ug SV2008002527A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005023301A DE102005023301B4 (de) 2005-05-13 2005-05-13 Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
DE102006016285A DE102006016285A1 (de) 2006-04-03 2006-04-03 Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat

Publications (1)

Publication Number Publication Date
SV2008002527A true SV2008002527A (es) 2008-03-27

Family

ID=37396913

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2006002527A SV2008002527A (es) 2005-05-13 2006-05-12 Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato ref. p-sv-80.273/ug

Country Status (37)

Country Link
US (2) US20080160004A1 (OSRAM)
EP (3) EP2116249B2 (OSRAM)
JP (2) JP2008540482A (OSRAM)
KR (2) KR20080028369A (OSRAM)
CN (2) CN101954083A (OSRAM)
AR (1) AR054123A1 (OSRAM)
AT (2) ATE555791T1 (OSRAM)
AU (1) AU2006245921A1 (OSRAM)
BR (1) BRPI0611443B8 (OSRAM)
CA (1) CA2608639C (OSRAM)
CL (2) CL2009002187A1 (OSRAM)
CR (1) CR9531A (OSRAM)
CY (2) CY1109261T1 (OSRAM)
DE (1) DE502006003617D1 (OSRAM)
DK (2) DK2116249T3 (OSRAM)
DO (1) DOP2006000110A (OSRAM)
EA (2) EA014664B1 (OSRAM)
EC (1) ECSP078001A (OSRAM)
ES (2) ES2325600T3 (OSRAM)
GT (1) GT200600200A (OSRAM)
HR (1) HRP20090418T1 (OSRAM)
IL (1) IL187340A (OSRAM)
MA (1) MA29448B1 (OSRAM)
MY (1) MY147362A (OSRAM)
NO (1) NO345807B1 (OSRAM)
PE (1) PE20061415A1 (OSRAM)
PL (2) PL2116249T3 (OSRAM)
PT (2) PT2116249E (OSRAM)
RS (2) RS50972B (OSRAM)
SG (1) SG169973A1 (OSRAM)
SI (2) SI2116249T1 (OSRAM)
SV (1) SV2008002527A (OSRAM)
TN (1) TNSN07418A1 (OSRAM)
TW (1) TWI380820B (OSRAM)
UY (1) UY29527A1 (OSRAM)
WO (1) WO2006120035A2 (OSRAM)
ZA (2) ZA200710811B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
CA2665788A1 (en) * 2006-07-06 2008-01-10 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical preparations for contraception and for preventing the risk of congenital malformations
EP1891959A1 (de) * 2006-08-14 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
MX2009010763A (es) * 2007-04-05 2009-10-28 Bayer Schering Pharma Ag NUEVO REGIMEN DE DROSPIRENONA/17ß-ESTRADIOL, PRODUCTO FARMACEUTICO COMBINADO Y CONJUNTO DE ELEMENTOS (KIT) PARA SU APLICACION.
EA201070715A1 (ru) * 2007-12-20 2011-02-28 Тева Вимен'С Хелс, Инк. Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции
TW200946542A (en) * 2008-03-10 2009-11-16 Vladimir Hanes New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
TW200942242A (en) * 2008-03-10 2009-10-16 Rolf Schurmann New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
MX356702B (es) 2010-04-15 2018-06-11 Bayer Ip Gmbh Formas de dosificación sólidas orales con dosis muy bajas para la hrt.
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP2617422A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate
EP2781214A1 (en) 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
CN104490887A (zh) * 2014-09-04 2015-04-08 连云港金康和信药业有限公司 (6s)-5-甲基-四氢叶酸钙盐的稳定药物组合物
MY195019A (en) 2015-06-18 2023-01-03 Estetra Sprl Orodispersible dosage unit containing an estetrol component
JP6866560B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
HUE054589T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Szájban diszpergálódó esztetrol tartalmú tabletta
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN106336444A (zh) * 2016-08-23 2017-01-18 国家卫生计生委科学技术研究所 一种新晶型炔雌醇
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK174724B1 (da) * 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
ZA939565B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.
US6083528A (en) * 1995-09-28 2000-07-04 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
AU7522896A (en) * 1995-10-27 1997-05-15 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
CN1122456C (zh) 1996-01-31 2003-10-01 南亚拉巴马医学科学基金会 含有天然的还原叶酸盐异构体的食品和维生素制品
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
UA68365C2 (en) * 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
CN1240387C (zh) * 1998-04-17 2006-02-08 奥索一麦克尼尔药品公司 含有叶酸的药用组合物及其用途和给药系统
US7014865B1 (en) 1998-10-19 2006-03-21 Merck Patent Gmbh Natural formulation for the treatment and prevention of depression, containing St. John's Wort and derivatives of dihydro- and tetrahydrofolic acid
CA2348693C (en) * 1998-10-19 2008-07-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
HU225779B1 (en) 1999-07-28 2007-08-28 Chinoin Gyogyszer Es Vegyeszet Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
ES2319750T3 (es) 1999-08-31 2009-05-12 Bayer Schering Pharma Aktiengesellschaft Composicion farmaceutica que comprende etinilestradiol y drospirenona para usar como anticonceptivo.
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US6479545B1 (en) 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
DE10022510A1 (de) 2000-05-10 2001-11-15 Basf Ag Zusammensetzungen enthaltend Folsäure und reduziertes Folat
CA2433949A1 (en) * 2000-12-14 2002-10-24 Tufts University Compositions and methods for treating an arthritic condition
US20030045510A1 (en) * 2000-12-15 2003-03-06 Schloss Caroline Maxine Estrogen-plus
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
US20040220118A1 (en) * 2001-02-02 2004-11-04 Bland Jeffrey S. Medical composition for balancing bodily processes
US20060034954A1 (en) * 2001-02-02 2006-02-16 Bland Jeffrey S Medical composition for balancing bodily processes
CA2476940C (en) * 2002-02-21 2011-11-01 Herman Jan Tijmen Coelingh Bennink Pharmaceutical compositions comprising one or more steroids, one or more tetrahydrofolate components and vitamin b12
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.

Also Published As

Publication number Publication date
GT200600200A (es) 2007-03-23
TWI380820B (zh) 2013-01-01
PE20061415A1 (es) 2007-01-26
MA29448B1 (fr) 2008-05-02
RS50972B (sr) 2010-10-31
ATE555791T1 (de) 2012-05-15
HRP20090418T1 (hr) 2009-09-30
EP2116249B1 (de) 2012-05-02
ZA200908894B (en) 2025-01-29
EA028530B1 (ru) 2017-11-30
CL2010000989A1 (es) 2011-02-18
NO345807B1 (no) 2021-08-16
CY1114403T1 (el) 2016-08-31
PL1888077T3 (pl) 2009-12-31
EP2298307A1 (de) 2011-03-23
KR20080028369A (ko) 2008-03-31
HK1118729A1 (en) 2009-02-20
JP2008540482A (ja) 2008-11-20
CL2009002187A1 (es) 2010-10-01
JP2013166753A (ja) 2013-08-29
US20080160004A1 (en) 2008-07-03
US10463666B2 (en) 2019-11-05
SI2116249T1 (sl) 2013-02-28
PL2116249T3 (pl) 2013-06-28
SG169973A1 (en) 2011-04-29
RS52651B (sr) 2013-06-28
EA200901393A1 (ru) 2010-02-26
ES2325600T3 (es) 2009-09-09
ZA200710811B (en) 2012-06-27
PT1888077E (pt) 2009-07-20
EP2116249B2 (de) 2023-04-05
CY1109261T1 (el) 2014-07-02
DOP2006000110A (es) 2012-06-15
WO2006120035A2 (de) 2006-11-16
KR101598735B1 (ko) 2016-03-02
WO2006120035A3 (de) 2007-02-15
EA200702349A1 (ru) 2008-04-28
BRPI0611443A2 (pt) 2010-09-08
BRPI0611443B1 (pt) 2020-07-21
CN101198332A (zh) 2008-06-11
CN101954083A (zh) 2011-01-26
EP1888077A2 (de) 2008-02-20
ES2387525T5 (es) 2024-07-05
UY29527A1 (es) 2006-12-29
AU2006245921A1 (en) 2006-11-16
ECSP078001A (es) 2008-01-23
ATE429917T1 (de) 2009-05-15
PT2116249E (pt) 2012-08-07
CR9531A (es) 2008-02-21
EP1888077B1 (de) 2009-04-29
IL187340A0 (en) 2011-08-01
US20160095860A1 (en) 2016-04-07
KR20140069175A (ko) 2014-06-09
TW200711651A (en) 2007-04-01
BRPI0611443B8 (pt) 2021-05-25
AR054123A1 (es) 2007-06-06
ES2387525T3 (es) 2012-09-25
JP5883810B2 (ja) 2016-03-15
MY147362A (en) 2012-11-30
DK1888077T3 (da) 2009-08-17
EP2116249A1 (de) 2009-11-11
DE502006003617D1 (de) 2009-06-10
SI1888077T1 (sl) 2009-10-31
EA014664B1 (ru) 2010-12-30
TNSN07418A1 (en) 2009-03-17
CA2608639C (en) 2013-04-30
DK2116249T3 (da) 2012-08-20
IL187340A (en) 2015-03-31
NO20076408L (no) 2008-02-12
CN101198332B (zh) 2012-07-18
CA2608639A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
SV2008002527A (es) Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato ref. p-sv-80.273/ug
ECSP099030A (es) Composición farmacéutica que contiene un ácido tetrahidrofólico
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
CL2017000381A1 (es) Nuevos compuestos de spiro[3h-indol-3,2'-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53
BR112023015715A2 (pt) Inibidor de cdk
CL2008003480A1 (es) Compuestos derivados de amino-pirimidina, con propiedades inmunomoduladoras y que actuan a traves de tlr7; proceso para preparar los compuestos; compuestos intermediarios; composicion y combinacion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos
AR058908A1 (es) Despachadores de rocio
CL2008003271A1 (es) Compuesto (2r)-2-[[(4-clorofenil)sulfonil][[2-fluoro-4-(1,2,4-oxadiazol-3-il)fenil]metil]amino]-5,5,5-trifluoropentanamida; composiciones farmaceuticas que lo contienen; y su uso en el tratamiento o retardo de la aparicion de la enfermedad de alzheimer, angiopatia amiloide cerebral, deterioro cognitivo leve y/o sindrome de down.
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
BRPI0919753B8 (pt) forma polimórfica de palmitoiletanolamida, composição farmacêutica para uso humano ou veterinário, método para a micronização da palmitoiletanolamida e palmitoiletanolamida ultramicronizada
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
CL2008001560A1 (es) Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico.
SV2009003366A (es) Estabilizacion de vitamina b12
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
CL2012000457A1 (es) Composicion farmaceutica oral que comprende el compuesto 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]piperazina y sus sales, en donde dicha composicion esta adaptada de manera que dicho compuesto no es liberado en el estomago; y su uso para el tratamiento de trastornos del animo, de ansiedad, de panico, entre otras enfermedades.
CL2007001961A1 (es) Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo.
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.
GT200600106A (es) Agentes endoparasiticidas
ES2422173T3 (es) Composiciones que contienen aecuorina y procedimientos de uso de las mismas
CL2008002163A1 (es) Derivados de 2-azetidina y 2-pirrolidina metanoaminas; sus procesos de obtencion; la composicion farmaceutica que los contienen; y sus usos.
SV2006002123A (es) Profarmacos de esteroides con accion androgenica ref. p-sv-78.334/msu
CR9563A (es) Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil)ftalazin-1-ilo] no micromizado, y sus sales

Legal Events

Date Code Title Description
FG Grant
FG Grant